Mylan Inc Launches Generic Rivastigmine Capsules in the UK

Strategic Insights -

Mylan Inc's UK-based subsidiary has launched Rivastigmine Capsules POM, a generic version of Novartis' Exelon Capsules, which is used to treat dementia in people with Alzheimer's disease. This marks Mylan's second recent first-to-market generic launch in the UK, following the successful launch of Modafinil tablets, the generic version of Cephalon's Provigil. The company's chairman and CEO, Robert J Coury, highlighted the importance of providing high-quality and affordable medicines to patients worldwide.

Key Takeaways:

  • Mylan's UK subsidiary has launched Rivastigmine Capsules POM, a generic version of Novartis' Exelon Capsules, for the treatment of dementia in people with Alzheimer's disease.
  • This marks Mylan's second recent first-to-market generic launch in the UK, following the successful launch of Modafinil tablets, the generic version of Cephalon's Provigil.
  • Mylan has a portfolio of over 350 products in the UK, with Rivastigmine capsules POM being added to the list.
  • Robert J Coury, Mylan's chairman and CEO, noted that this launch is a testament to the company's commitment to providing high-quality and affordable medicines to patients worldwide.
  • Mylan is a leading generic and specialty pharmaceutical company with a presence in over 150 countries and territories.
  • The company operates one of the world's largest active pharmaceutical ingredient manufacturers and has a robust product pipeline.

Statistics:

  • Rivastigmine capsules POM had UK sales of approximately 7.9 million for the last 12 months ending 30 June 2011, according to IMS Health.
  • Mylan ranks among the leading generic and specialty pharmaceutical companies in the world.
  • Mylan maintains a portfolio of over 350 products in the UK and operates in more than 150 countries and territories.

Sources:

  • Mylan Inc
  • IMS Health
  • Contify.com
  • Domain-b.com